GlassScriptPhysician profile
Stanley B Czajkowski
NPI 1902878507
$14,356.94
in general payments reported to CMS, 2019-2025
49 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,114 · 2020: $664 · 2021: $1,355 · 2022: $4,820 · 2023: $2,183 · 2024: $1,407 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,385 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,385.04 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,479.20 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,212.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,041.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $845.23 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $756.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $682.35 | 2019-2023 | Breztri, Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $627.62 | 2021-2025 | |
| Abbott Laboratories | $588.05 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Otsuka America Pharmaceutical, INC. | $430.94 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $387.28 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $372.69 | 2019-2021 | |
| Daiichi Sankyo INC. | $321.65 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $266.65 | 2020-2025 | Arexvy |
| Janssen Pharmaceuticals, INC | $235.79 | 2019-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.40 | 2020-2023 | Xifaxan, Trulance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Czajkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.